Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil-based chemotherapy: Efficacy and prognostic factors

Tumori

Volumn 89, Issue 2, 2003, Pages 141-145

  Karaoǧlu, Aziz ^a   Yalcin, Suayib ^a   Tekuzman, Gülten ^a   Kars, Ayse ^a   Çelik, Ismail ^a   Güler, Nilüfer ^a   Özişik, Yavuz ^a   Türker, Alev ^a   Barişta, Ibrahim ^a   Güllü, Ibrahim ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Colorectal cancer; Irinotecan; Recurrent

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; FLUOROURACIL; FOLINIC ACID; GRANISETRON; IRINOTECAN; LEVAMISOLE; LOPERAMIDE; ONDANSETRON; SEROTONIN ANTAGONIST; TROPISETRON; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; AGE; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; MALE; METASTASIS; NAUSEA; PROGNOSIS; SACCHAROMYCES; THROMBOCYTOPENIA; TREATMENT FAILURE; TURKEY (REPUBLIC); VOMITING;

EID: 17144435198     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160308900207     Document Type: Article

References (30)

1. Pisani P, Parkin DM, Ferlay J: Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer, 55: 891-903, 1993.
2. Coleman M, Esteve J: Trends in cancer incidence, survival, and mortality. IARC Sci Pub, 121: 1, 1993.
3. Burkitt DP: Epidemiology of cancer of the colon and rectum. Dis Colon Rectum, 30: 1071-1082, 1993.
4. Wingo PA, Tong T, Bolden S: Cancer statistics 1995. CA Cancer J Clin, 45: 8-30, 1995.
5. Cunningham D, Findlay M: The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer, 29A: 2077-2079, 1993.
6. Shimida Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N: Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer. J Clin Oncol, 11: 909-913, 1993.
7. Sasaki Y, Ohtsu A, Shimida Yono K, Saijo N: Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst, 86: 1096-1098, 1994.
8. Rothenberg ML, Kuhn JG, Burris HA 3rd, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodrigez GI, Rock MK, Vonhoff DD: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol, 11:2194-2204, 1993.
9. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol, 13: 210-221, 1995.
10. WHO handbook for reporting results of cancer treatment. WHO offset publication No. 48 Geneva, World Health Organization, 1979.
11. NCI-NIH National Cancer Institute, National Institute of Health. Common toxicity criteria, version 2.0. NCI-NIH Bethesda, MD, pp 1-80, 1999.
12. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc, 53: 457-481, 1958.
13. Cox DR, Oakes D: Analysis of survival data, Chapman and Hall, pp 80-90, New York, 1984.
14. Norusis MJ: SPSS for Windows Base System User's Guide Release 6.0., First edition, SPSS Inc, Chicago, 1993.
15. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB: Preliminary pharmacological and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep, 54: 461-470, 1970.
16. Gallo RC, Whang-Peng J, Adamson RH: Studies on the antitumour activity, mechanism of action and cell cycle effects of camptothecin. J Natl Cancer Inst, 46: 789-795, 1971.
17. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato H: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumour effect of CPT-11. Cancer Res, 51: 4187-4191, 1991.
18. Giovenella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M: DNA topoisomerase 1-targeted chemotherapy of human colon cancer in xenografts. Science, 246: 46-48, 1989.
19. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, Taguchi T: Phase I study of weekly inrtravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J Natl Cancer Inst, 83: 1164-1168, 1991.
20. Fukuoka M, Negoro S, Niitani H, Furue H, Hasegawa K, Hara Y, Hara N, Taguchi T: A phase I clinical study of weekly administrations of CPT-11 in lung cancer. Jpn J Cancer Chemother, 17: 993-997, 1991.
21. Armand JP, Extra YM, Catimel G, Abierges D, Marty M, Clavel M: Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Ann Oncol, 7: 837-842, 1996.
22. Canal P, Gay C, Dezeuze A, Douilliard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A: Pharmacokinetics and pharmacodynamics of irinotecan hydrochloride (CPT-11) during a phase II clinical trial in colorectal cancer. J Clin Oncol, 14: 2688-2695, 1996.
23. Conti JA, Kemeny N, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol, 14: 709-715, 1996.
24. Pitot HC, Wender DB, O'Connell MJ, Schroder G, Goldberg RM, Rubin J, Mailliard JA, Knost JA, Ghosh J, Kirscling RJ, Lewitt R, Windschitl HE: Phase II trial of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol, 15: 2910-2919, 1997.
25. Rougier P, Mitry E: Colorectal cancer chemotherapy: irinotecan. Semin Oncol, 27(Suppl 10): 138-143, 2000.
26. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham JA, Awad L, Jacques C, Herait P: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352: 1413-1418, 1998.
27. Yalcin S, Güler N, Kansu E, Ertenli I, Gullu I, Kars A, Akpek G, Barista I, Tekuzman G, Baltali E: Granulocyte-colony stimulating factor (G-CSF) administration for chemotherapy-induced neutropenia. Hematology, 1: 155-162, 1996.
28. Yalcin S, Tekuzman G, Baltali E, Ozisik Y, Barista I: Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic single-day chemotherapy: a randomized study. Am J Clin Oncol, 22: 94-96, 1999.
29. Yalcin S, Güllü I: Comparison of CEA and CA 125 levels in the ascites and serum of patients with ovarian carcinoma. Cancer Invest, 16: 426-427, 1998.
30. Güllü I, Yalcin S, Tekuzman G, Kars A, Baltali E, Güler N, Barista I, Firat D, Bekdik C, Koray Z: Tumor markers in effusions: a comparative study of tumor marker levels in sera and effusions. In: Use of biomarkers in assessing health and environmental impacts of chemical pollutants. Travis CC (Ed), pp 265-271, Plenum Press, New York, 1993.